SmokingNCT02026440
Evaluation of An Oral Fluid Collection Device
An observational study of Smoking, run by Avioq, Inc. at 1 site in United States.
Trial summary
The VioOne Oral Fluid Sample Collection Device can be used to collect human oral fluid samples for detection of cotinine using an ELISA cotinine assay. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Smoking
- How many people
- 250 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2013to Apr 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Healthy and adult population
Who may be able to join
- healthy adults (aged 18 or older)
Who cannot join
- individuals with significant health problems.
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
Avioq
Research Triangle Park, North Carolina, 27709
Krista Reddington, BS, 919-314-5535 ext. 1003, reddingtonk@avioq.com
Krista Reddington, BS
About this study
Official title: Collection and Testing of Human Oral Fluid Samples/VioOne OF Sample Collection Device
The VioOne Oral Fluid Sample Collection Device can be used to collect human oral fluid samples for detection of cotinine using an ELISA cotinine assay.
Read the detailed description
The Study to evaluate the VioOne Oral Fluid Sample Collection Device (herein referred to as VioOne Device) will consist of several sub-studies as described below:
- Recovery Study
This study will determine the percent recovery of cotinine spiked into the oral fluid of non-smokers collected with the VioOne Sample Collection Device.
- Sample collection Oral fluid will be collected per the VioOne package insert from five individuals self-reported to be non-smokers. The samples collected will then be individually spiked with cotinine to concentrations of 0, 5, 10, 15 or 25ng/mL. Two sets of each concentration will be prepared. One set will be stored at 2-8°C prior to testing and one set will be shipped per routine shipping conditions and tested upon return.
- Testing Each sample will then be tested in duplicate with the Calbiotech Cotinine ELISA assay and the percent recovery will be calculated for each level by comparing the detected concentrations to the spiked concentrations.
- Data Analysis Percent recovery will be calculated for each level by comparing the detected concentrations to the spiked concentrations.
- Sensitivity/Accuracy Study The study goal is to show that the Calbiotech Cotinine ELISA is capable of distinguishing smokers from nonsmokers when oral fluid samples collected with the VioOne Sample Collection Device are used.
- Sample Collection A minimum of two study sites will participate in this study. Approximately 218 individuals will be enrolled in this study. At least 58 collected samples must be from self-declared smokers. Oral fluid samples will be collected from individuals, who will give the informed consent and self-report in an anonymous fashion whether or not the individual is a smoker and number of cigarettes smoked per day on average. Two samples will be collected from each individual for this study. One sample will be collected using the VioOne Collection Device and one will be collected using a commercially available saliva collection cup. There will be no age, gender or race criteria for enrolling the patients.
- Testing All samples collected with the VioOne Sample Collection Device will be tested with the Calbiotech Cotinine ELISA and the neat saliva samples collected with the saliva collection cups will be tested by GC/MS, the latter being the gold standard method.
- Data Analysis The GC/MS results will be used as the gold standard for assessing the clinical sensitivity and specificity of the assay using oral fluid samples collected with the VioOne Oral Fluid Collection Device.
- Assay Specificity Study Beverages and Household materials will be tested for interference in the detection of cotinine in oral fluid.
- Sample Collection Oral Fluid samples will be collected from individuals self-reported as non-smokers and the resulting sample/buffer matrix will be pooled. The pool will be divided into 15 aliquots and individually spiked each of the following 14 compounds. One aliquot form the pool will remain un-spiked. Each spiked aliquot will then be further divided into three aliquots. One aliquot will remain spiked with the compound only, one aliquot will be further spiked with 5ng/mL of Cotinine and one aliquot will be further spiked with 15ng/mL Cotinine.
- Testing Each sample will then be tested in duplicate. The following compounds will each be spiked at a final concentration of 10% unless otherwise noted: Sugar Water Alcohol (Ethanol) Toothpaste Whole Blood (10mg/mL) Cranberry Juice Hydrogen Peroxide Baking Soda Sodium Chloride Orange Juice Cola Cough Syrup Antiseptic Water Hemoglobin (10mg/mL)
- Data Analysis Results will be compared to the expected performance as measured in the precision study. (the precision study does not require the use of collected human oral fluid)
- Assay Specificity Study
The effect of potential food and other oral cavity contaminants will be evaluated in a timed study.
- Sample Collection Ten individuals self-reported to be non-smokers will be recruited for this study. One sample will be collected using the VioOne Sample Collection Device from each individual immediately prior to the start of the study. Each individual will then be given a piece of hard candy to consume. Additional samples will be collected with VioOne immediately post consumption, ten minutes post consumption then every thirty minutes up to three hours. After all samples are collected each sample will be divided into two aliquots. One aliquot will be spiked with 5ng/mL cotinine and one aliquot will be spiked with 15ng/mL cotinine.
- Testing Each sample/spike/time point will be tested in triplicate
- Data Analysis Results will be compared to the expected performance as measured in the precision study. (the precision study does not require the use of collected human oral fluid)
- Stability of sample in sample collection buffer A study will be performed to establish the stability of samples stored in sample collection buffer at various temperatures over time.
- Sample Collection Oral Fluid samples will be collected from individuals self-reported as non-smokers and the resulting sample/buffer matrix will be pooled. The pool will be split into three aliquots. One aliquot will be spiked with 7.5ng/mL cotinine, one aliquot will be spiked with 10ng/mL cotinine and one aliquot will remain non-spiked. Each one of the spikes and the non-spike will be aliquoted into four tubes and stored at -20 oC, 2-8oC, room temperature and 37oC.
- Testing Each sample will be tested in eight replicates at Day 0, 7, 14, 21, 28 and 35.
- Data analysis
The sample is considered stable at the test time point when the 95% confidence interval for the cotinine concentration at a given day for the sample overlaps that of Day 0.
- ELISA and Device Stability
A long term stability study will be performed to establish the stability and expiration dating of the Calbiotech Cotinine ELISA assay along with the VioOne Sample collection Device.
- Sample Collection At each testing time point, samples from three individuals will be collected. Each individual will provide three samples- one with each of three lots of VioOne Sample Collection Devices. The resulting sample/buffer matrix obtained from each lot of VioOne Sample Collection Device will be pooled (a total of 3 individual samples per pool and a total of 3 pools). The resulting pools will then be divided into two aliquots. One aliquot will be spiked with 5ng/mL cotinine and 25ng/mL cotinine.
- Testing Each spiked sample will be tested in eight replicates over a period of 21 months. Over the course of testing, three ELISA assay lots will be used.
- Data Analysis
The Calbiotech Cotinine ELISA assay and the VioOne Sample Collection Device are considered stable when the samples tested at each time point produce results within the 95% confidence interval for the cotinine concentration overlaps that of Day 0.
- Conditions
- Smoking
- Keywords
- oral fluid collection device cotinine detection
- Medical subject headings
- Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Smokers | Those who smoke at least one cigarette a day. | |
| Non smokers | Those who have not smoked for at least one week when the sample is collected. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of Nicotine in Collected Oral Fluid Samples
ELISA assay in comparison with the Mass-spec method will be used to detect the presence of nicotine in the oral fluid samples collected with the VioOne collection device.
Measured: Within one week of sample collection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2014 (estimated)
- Study startDec 2013
- Primary completionMar 2014 (estimated)
- Study completionApr 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SmokingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Avioq, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Clinical Reference Laboratory
- Responsible party
- Sponsor
- Investigators
- Krista Reddington, B.S., Study chair, Avioq, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02026440
- Sponsor's protocol ID
- 200008
- Other IDs
- FDA Pre-Submission Q130748
- Status last verified
- Dec 2013
- First submitted
- 12 Dec 2013
- Last updated
- 3 Jan 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jan 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Collection and Testing of Human Oral Fluid Samples/VioOne OF Sample Collection Device
- ClinicalTrials.gov ID
- NCT02026440
- Acronym / sponsor ID
- 200008
- Conditions
- Smoking
- Keywords
- oral fluid collection device cotinine detection
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Avioq, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Clinical Reference Laboratory
- Study start
- Dec 2013
- Primary completion
- Mar 2014 (estimated)
- Study completion
- Apr 2014 (estimated)
- First posted
- 3 Jan 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The VioOne Oral Fluid Sample Collection Device can be used to collect human oral fluid samples for detection of cotinine using an ELISA cotinine assay.
Detailed description
The Study to evaluate the VioOne Oral Fluid Sample Collection Device (herein referred to as VioOne Device) will consist of several sub-studies as described below:
- Recovery Study
This study will determine the percent recovery of cotinine spiked into the oral fluid of non-smokers collected with the VioOne Sample Collection Device.
- Sample collection Oral fluid will be collected per the VioOne package insert from five individuals self-reported to be non-smokers. The samples collected will then be individually spiked with cotinine to concentrations of 0, 5, 10, 15 or 25ng/mL. Two sets of each concentration will be prepared. One set will be stored at 2-8°C prior to testing and one set will be shipped per routine shipping conditions and tested upon return.
- Testing Each sample will then be tested in duplicate with the Calbiotech Cotinine ELISA assay and the percent recovery will be calculated for each level by comparing the detected concentrations to the spiked concentrations.
- Data Analysis Percent recovery will be calculated for each level by comparing the detected concentrations to the spiked concentrations.
- Sensitivity/Accuracy Study The study goal is to show that the Calbiotech Cotinine ELISA is capable of distinguishing smokers from nonsmokers when oral fluid samples collected with the VioOne Sample Collection Device are used.
- Sample Collection A minimum of two study sites will participate in this study. Approximately 218 individuals will be enrolled in this study. At least 58 collected samples must be from self-declared smokers. Oral fluid samples will be collected from individuals, who will give the informed consent and self-report in an anonymous fashion whether or not the individual is a smoker and number of cigarettes smoked per day on average. Two samples will be collected from each individual for this study. One sample will be collected using the VioOne Collection Device and one will be collected using a commercially available saliva collection cup. There will be no age, gender or race criteria for enrolling the patients.
- Testing All samples collected with the VioOne Sample Collection Device will be tested with the Calbiotech Cotinine ELISA and the neat saliva samples collected with the saliva collection cups will be tested by GC/MS, the latter being the gold standard method.
- Data Analysis The GC/MS results will be used as the gold standard for assessing the clinical sensitivity and specificity of the assay using oral fluid samples collected with the VioOne Oral Fluid Collection Device.
- Assay Specificity Study Beverages and Household materials will be tested for interference in the detection of cotinine in oral fluid.
- Sample Collection Oral Fluid samples will be collected from individuals self-reported as non-smokers and the resulting sample/buffer matrix will be pooled. The pool will be divided into 15 aliquots and individually spiked each of the following 14 compounds. One aliquot form the pool will remain un-spiked. Each spiked aliquot will then be further divided into three aliquots. One aliquot will remain spiked with the compound only, one aliquot will be further spiked with 5ng/mL of Cotinine and one aliquot will be further spiked with 15ng/mL Cotinine.
- Testing Each sample will then be tested in duplicate. The following compounds will each be spiked at a final concentration of 10% unless otherwise noted: Sugar Water Alcohol (Ethanol) Toothpaste Whole Blood (10mg/mL) Cranberry Juice Hydrogen Peroxide Baking Soda Sodium Chloride Orange Juice Cola Cough Syrup Antiseptic Water Hemoglobin (10mg/mL)
- Data Analysis Results will be compared to the expected performance as measured in the precision study. (the precision study does not require the use of collected human oral fluid)
- Assay Specificity Study
The effect of potential food and other oral cavity contaminants will be evaluated in a timed study.
- Sample Collection Ten individuals self-reported to be non-smokers will be recruited for this study. One sample will be collected using the VioOne Sample Collection Device from each individual immediately prior to the start of the study. Each individual will then be given a piece of hard candy to consume. Additional samples will be collected with VioOne immediately post consumption, ten minutes post consumption then every thirty minutes up to three hours. After all samples are collected each sample will be divided into two aliquots. One aliquot will be spiked with 5ng/mL cotinine and one aliquot will be spiked with 15ng/mL cotinine.
- Testing Each sample/spike/time point will be tested in triplicate
- Data Analysis Results will be compared to the expected performance as measured in the precision study. (the precision study does not require the use of collected human oral fluid)
- Stability of sample in sample collection buffer A study will be performed to establish the stability of samples stored in sample collection buffer at various temperatures over time.
- Sample Collection Oral Fluid samples will be collected from individuals self-reported as non-smokers and the resulting sample/buffer matrix will be pooled. The pool will be split into three aliquots. One aliquot will be spiked with 7.5ng/mL cotinine, one aliquot will be spiked with 10ng/mL cotinine and one aliquot will remain non-spiked. Each one of the spikes and the non-spike will be aliquoted into four tubes and stored at -20 oC, 2-8oC, room temperature and 37oC.
- Testing Each sample will be tested in eight replicates at Day 0, 7, 14, 21, 28 and 35.
- Data analysis
The sample is considered stable at the test time point when the 95% confidence interval for the cotinine concentration at a given day for the sample overlaps that of Day 0.
- ELISA and Device Stability
A long term stability study will be performed to establish the stability and expiration dating of the Calbiotech Cotinine ELISA assay along with the VioOne Sample collection Device.
- Sample Collection At each testing time point, samples from three individuals will be collected. Each individual will provide three samples- one with each of three lots of VioOne Sample Collection Devices. The resulting sample/buffer matrix obtained from each lot of VioOne Sample Collection Device will be pooled (a total of 3 individual samples per pool and a total of 3 pools). The resulting pools will then be divided into two aliquots. One aliquot will be spiked with 5ng/mL cotinine and 25ng/mL cotinine.
- Testing Each spiked sample will be tested in eight replicates over a period of 21 months. Over the course of testing, three ELISA assay lots will be used.
- Data Analysis
The Calbiotech Cotinine ELISA assay and the VioOne Sample Collection Device are considered stable when the samples tested at each time point produce results within the 95% confidence interval for the cotinine concentration overlaps that of Day 0.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Smokers | – | –Those who smoke at least one cigarette a day. |
| Non smokers | – | –Those who have not smoked for at least one week when the sample is collected. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Healthy and adult population
Key inclusion criteria (1 listed)
- healthy adults (aged 18 or older)
Key exclusion criteria (1 listed)
- individuals with significant health problems.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Presence of Nicotine in Collected Oral Fluid Samples
Time frame: Within one week of sample collection
ELISA assay in comparison with the Mass-spec method will be used to detect the presence of nicotine in the oral fluid samples collected with the VioOne collection device.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jan 2014.
Related trials for Smoking
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Recruiting
Effectiveness of Volitional Help Sheets as an Adjunct to Treatment to Promote Behavior Change: A Pilot Study on Smoking
Tobacco Dependence
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Krista Reddington, B.S. study chair
Avioq, Inc.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Smoking, run by Avioq, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of Nicotine in Collected Oral Fluid Samples (time frame: Within one week of sample collection). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2014.